Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $11.40.
A number of research firms have recently issued reports on VRCA. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. Needham & Company LLC reissued a “hold” rating and issued a $12.00 target price on shares of Verrica Pharmaceuticals in a research report on Thursday, October 3rd. Royal Bank of Canada reduced their price target on Verrica Pharmaceuticals from $13.00 to $11.00 and set an “outperform” rating for the company in a report on Friday, October 4th. Finally, TD Cowen dropped their target price on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a report on Monday.
View Our Latest Research Report on VRCA
Verrica Pharmaceuticals Price Performance
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $4.70 million. As a group, equities analysts anticipate that Verrica Pharmaceuticals will post -1.58 EPS for the current year.
Hedge Funds Weigh In On Verrica Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in VRCA. Simplify Asset Management Inc. bought a new position in Verrica Pharmaceuticals during the 2nd quarter worth about $2,041,000. Renaissance Technologies LLC acquired a new position in shares of Verrica Pharmaceuticals in the second quarter valued at about $332,000. Quest Partners LLC bought a new position in Verrica Pharmaceuticals during the 2nd quarter worth $50,000. Rhumbline Advisers increased its stake in Verrica Pharmaceuticals by 20.4% in the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock valued at $194,000 after acquiring an additional 4,514 shares during the last quarter. Finally, Key Financial Inc bought a new position in Verrica Pharmaceuticals in the second quarter valued at about $69,000. 42.45% of the stock is owned by institutional investors.
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
See Also
- Five stocks we like better than Verrica Pharmaceuticals
- The How and Why of Investing in Gold Stocks
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Canadian Penny Stocks: Can They Make You Rich?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Roth IRA Calculator: Calculate Your Potential Returns
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.